Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs
WiredAPR 28
The FDA's decision to halt compounded versions protects patient safety and upholds quality standards, as these copycat drugs bypass crucial regulatory oversight and may pose serious health risks. The shortage is genuinely over; patients should only use FDA-approved medications that have undergone rigorous testing and manufacturing controls.
Millions of patients who cannot afford brand-name medications will lose access to life-changing, more accessible treatment options. The FDA acted prematurely in declaring the shortage over, and ending compounding will worsen supply issues while forcing desperate patients to seek potentially dangerous counterfeit drugs online.
Pharmaceutical patents grant monopolies that prioritize profit over people. Life-saving drugs become unaffordable, delaying or denying care to millions. Innovation shouldn't come at the cost of human lives. The current patent system stifles competition, inflates prices, and deepens inequality — turning medicine into a privilege, not a right. Health should never be a commodity.